As filed · Orchid Pharma Limited has informed the Exchange regarding 'Orchid Pharma Limited has informed the Exchange regarding 'Intimation related to the Scheme of Amalgamation of Dhanuka LaboratoriesLimited (
Orchid Pharma Limited has announced that the Hon'ble National Company Law Tribunal (NCLT) has pronounced an order regarding the Scheme of Amalgamation with Dhanuka Laboratories Limited. The order includes directions for convening meetings of equity shareholders and unsecured creditors of both companies, while meetings for equity shareholders of Dhanuka Laboratories and secured creditors have been dispensed with due to prior consents. A copy of the NCLT order has been…
A merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
Prior statements by this company that CapitSignal has recorded changing.
We'll probably have the exact number, say, after a few months' time.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
So, as such -- we have not considered very significant capex in the next financial year.
So we hope we can continue between 10% to 15% again this year.
we hope to have better sales on Q-o-Q basis.
